Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035253 | 0.82 | NOS3 (0.46) | NOS3NOS1LMNATOP2ATOP2B | |
| SCHEMBL15972019 | 0.80 | CYP17A1 (0.48) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL30530906 | 0.80 | CYP17A1 (0.48) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL18072998 | 0.79 | NAMPT (0.48) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL14428036 | 0.78 | NAMPT (0.54) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL24951504 | 0.77 | CYP17A1 (0.45) | CYP17A1NAMPTMAPK14LMNATOP2A | |
| SCHEMBL17916740 | 0.77 | CYP17A1 (0.45) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL30530861 | 0.77 | CYP17A1 (0.45) | CYP17A1NAMPTMAPK14HDAC3HDAC8 | |
| SCHEMBL30202833 | 0.77 | CYP17A1 (0.45) | CYP17A1NAMPTMAPK14LMNATOP2A | |
| SCHEMBL2256900 | 0.76 | NOS3 (0.45) | NOS3NOS1HPGDSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | CYP17A1 489/4885NAMPT 1506/4885NOS3 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.